PPD beefs up its therapeutics team with new leadership

Pushpin showing North Carolina on a map
Darell Heiselman, D.O., will lead PPD’s cardiovascular and critical care niches, while David Klein, M.D., has been charged with overseeing endocrinology, metabolism and diabetes. (Getty/Creative RF)

Pharmaceutical Product Development, a North Carolina-based CRO, is adding more punch to its therapeutics offerings with new leadership overseeing a number of prime areas.

Darell Heiselman, D.O., will lead PPD’s cardiovascular and critical care niches, while David Klein, M.D., has been charged with overseeing endocrinology, metabolism and diabetes.

“In their new roles, Darell and David will help develop cross-functional, integrated product development plans and assist with the design of clinical trials to provide therapeutic, protocol and site development expertise for our clients and their product,” Rob Dow, PPD’s chief medical officer, said in a statement.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

Heiselman has been named vice president of global product development. In his 23 years of practice, he developed a critical care center of excellence and performed more than 60 clinical trials in critical care, cardiology, nutritional support and stroke. Before PPD, Heiselman spent 11 years at Eli Lilly as a clinical research physician.

Klein, who is board-certified in pediatrics with a subspecialty board certification in pediatric endocrinology, has also been named a vice president of global product development. He has extensive experience managing diabetes and endocrine clinical trials, as well as trials in the therapeutic areas of pediatrics, rare disease, obesity, lipid metabolism, nonalcoholic steatohepatitis and celiac disease. He previously served as medical director at Medpace and as senior director of clinical development at Mannkind Corp.

Read more on

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.